阿斯利康股票将在上市级别升级后开始在美国交易

Core Viewpoint - AstraZeneca is upgrading its stock listing to replace its American Depositary Receipts (ADRs) on Nasdaq, starting trading on the New York Stock Exchange, reflecting a strategic shift towards the U.S. market, which accounts for nearly half of its revenue [1][3][4] Group 1: Company Strategy - The move aims to equalize AstraZeneca's listing status across the UK, Sweden, and the U.S., highlighting the increasing importance of the U.S. market for the company's business [1][3] - CEO Pascal Soriot's strategy focuses on growth in the largest pharmaceutical market, leading to a relative decrease in reliance on the domestic market [1][4] - AstraZeneca has committed to investing $50 billion in the U.S. by 2030, while pausing a £200 million ($274 million) expansion plan at its UK headquarters due to pressures from U.S. import tax policies [1][4] Group 2: Market Dynamics - The transition allows U.S. investors to purchase AstraZeneca's common stock directly, potentially diminishing the significance of its London listing [1][3] - Peel Hunt's research suggests that the trading focus of AstraZeneca's stock may gradually shift to the U.S. market, with a possibility of relocating its primary listing from London to the U.S. in the long term [4] - The change will exempt investors from paying the UK stock transaction stamp duty, which could result in an annual loss of £200 million in tax revenue for the UK Treasury [4] Group 3: Industry Trends - The trading volume of UK companies' ADRs has surged, with a reported increase of over 80% for 20 companies in the FTSE 100 index from 2019 to 2024 [2][5] - AstraZeneca's ADR trading volume rose by 34% over the same period, while its London market stock trading volume increased by less than 8% [5] - The U.S. market is characterized by larger scale and stronger liquidity, attracting high-growth companies, while the UK market is often seen as undervalued and dominated by traditional economic sectors [5]